FibroGen Inc. Files 8-K Report

TL;DR

FibroGen filed an 8-K, mostly boilerplate, no major news yet.

AI Summary

On August 18, 2025, FibroGen, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events or financial updates detailed in the provided text. The report was filed as of August 18, 2025, and pertains to FibroGen, Inc., a Delaware-incorporated company in the pharmaceutical preparations sector.

Why It Matters

This 8-K filing indicates FibroGen, Inc. is fulfilling its reporting obligations with the SEC, though the specific details of the "Other Events" or "Financial Statements and Exhibits" are not elaborated in this excerpt.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain information that would indicate a change in risk for the company.

Key Players & Entities

• FibroGen, Inc. (company) — Registrant
• 350 Bay Street Suite 100 #6009 (location) — Principal Executive Offices
• San Francisco, California (location) — City, State of Principal Executive Offices
• 94133 (location) — Zip Code of Principal Executive Offices
• 415 978-1200 (phone_number) — Registrant's Telephone Number
• August 18, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se

Filing Documents

• fgen-20250818.htm (8-K) — 50KB
• fgen-ex99_1.htm (EX-99.1) — 10KB
• 0000950170-25-109571.txt ( ) — 167KB
• fgen-20250818.xsd (EX-101.SCH) — 24KB
• fgen-20250818_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On August 18, 2025, FibroGen, Inc. (the "Company") issued a press release in which the Company announced that it received China regulatory approval for the sale of FibroGen International (Hong Kong) Ltd., (including its subsidiaries, "FibroGen China") to AstraZeneca Treasury Limited ("AstraZeneca"), pursuant to the Share Purchase Agreement, dated February 20, 2025. After review, the China State Administration for Market Regulation decided not to prohibit the proposed acquisition of FibroGen China by AstraZeneca. The closing of the transaction is subject to customary closing conditions and deliverables, and is expected to close in the third quarter of 2025. FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. agreed to sell all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. (including all of its roxadustat assets in China) to AstraZeneca, the Company's long-time commercialization partner for roxadustat in greater China and South Korea. FibroGen will retain the rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas Pharma Inc., our collaboration partner in Europe, Japan, and certain other territories. A copy of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: August 18, 2025 By: /s/ John Alden John Alden General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR